. Author manuscript; available in PMC: 2023 May 1.

Published in final edited form as: Lancet Haematol. 2022 May;9(5):e350–e360. doi: 10.1016/S2352-3026(22)00076-X

Table 1:

Patient Demographics

Characteristic^*	Overall, N = 279	IC, N = 194	VEN, N = 85	p-value
Age	49 (39-57)	51 (41-57)	45 (37-56)	0.063
Sex, male	131 / 279 (47%)	87 / 194 (45%)	44 / 85 (52%)	0.28
BM Blast ^ , %**	55 (32 - 75)	56 (33 - 77)	55 (27 - 72)	0.11
AML Type				0.0088
De novo	243 / 279 (87%)	176 / 194 (91%)	67 / 85 (79%)
High-risk MDS	3 / 279 (1%)	-	3 / 85 (4%)
sAML	16 / 279 (6%)	8 / 194 (4%)	8 / 85 (9%)
tAML	17 / 279 (6%)	10 / 194 (5%)	7 / 85 (8%)
ELN Risk Group				0.23
Favorable	53 / 279 (19%)	32 / 194 (16%)	21 / 85 (25%)
Intermediate	96 / 279 (34%)	67 / 194 (35%)	29 / 85 (34%)
Adverse	130 / 279 (47%)	95 / 194 (49%)	35 / 85 (41%)
Cytogenetics				0.57
Adverse/Complex	80 / 279 (29%)	58 / 194 (30%)	22 / 85 (26%)
Diploid	133 / 279 (48%)	93 / 194 (48%)	40 / 85 (47%)
Favorable	1 / 279 (1%)	-	1 / 85 (1%)
Insufficient/Unknown	11 / 279 (4%)	7 / 194 (4%)	4 / 85 (5%)
Other intermediate	53 / 279 (19%)	35 / 194 (18%)	18 / 85(21%)
Molecular mutations
NPM1 Mutated	71 / 276 (26%)	51 / 191 (27%)	20 / 85 (24%)	0.57
IDH1 Mutated	19 / 250 (8%)	12 / 165 (7%)	7 / 85 (8%)	0.78
IDH2 Mutated	33 / 250 (13%)	23 / 165 (14%)	10 / 85 (12%)	0.63
FLT3 mutated^†	88/ 279 (32)	66 / 194 (34%)	22 / 85 (26%)
FLT3-D835	24 / 277 (9%)	12 / 192 (6%)	12 / 85 (14%)	0.032
FLT3- ITD	70 / 278 (25%)	58 / 193 (30%)	12 / 85 (14%)	0.0048
FLT3 inhibitor	60 / 88 (68%)	51 /66 (77%)	9 / 22 (41%)	0.0015
RUNX1 Mutated	20 / 221 (9%)	9 / 136 (7%)	11 / 85 (13%)	0.11
ASXL1 Mutated	28 / 248 (11%)	20 / 163 (12%)	8 / 85 (9%)	0.49
TP53 Mutated	20 / 241 (8%)	15 / 156 (10%)	5 / 85 (6%)	0.32

All variables reported as N(%) or median (IQR);

^**

Includes patients with extramedullary AML;

^†

Concurrent FLT3-ITD and TKD mutations were present in 6 patients.